It is very uncertain whether methionine and supportive treatment changes mortality compared with supportive treatment (very low certainty).
It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower anaphylactoid symptoms compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether oral changes nausea compared with intravenous acetylcysteine (very low certainty).
It is very uncertain whether oral changes vomiting compared with intravenous acetylcysteine (very low certainty).
Intravenous acetylcysteine may leads to lower mortality compared with placebo (low certainty).
Methionine and supportive treatment may leads to lower hepatotoxicity compared with supportive treatment (low certainty).
It is very uncertain whether initial infusion rate of intravenous acetylcysteine over 15 minutes changes hepatotoxicity compared with 60 minutes (very low certainty).
Initial infusion rate of intravenous acetylcysteine over 15 minutes may leads to lower any adverse event compared with 60 minutes (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether charcoal haemoperfusion changes mortality compared with no intervention (very low certainty).
It is very uncertain whether cysteamine changes mortality compared with no intervention (very low certainty).
Cysteamine may leads to lower hepatotoxicity (aspartate aminotransferase > 1000 IU/L) compared with no intervention (low certainty).